Un groupe témoin est constitué de participants similaires au groupe traité, mais sans intervention.
Groupes témoinsMéthodes de recherche
#2
Quel est le rôle d'un groupe témoin ?
Il permet d'évaluer l'effet d'un traitement en comparant les résultats avec ceux du groupe traité.
Groupes témoinsÉvaluation des traitements
#3
Comment choisir un groupe témoin ?
Le choix doit se baser sur des critères d'inclusion similaires à ceux du groupe traité.
Groupes témoinsCritères d'inclusion
#4
Les groupes témoins sont-ils toujours nécessaires ?
Oui, ils sont essentiels pour établir des comparaisons valides dans les études cliniques.
Groupes témoinsEssais cliniques
Symptômes
2
#1
Les groupes témoins montrent-ils des symptômes ?
Non, ils ne reçoivent pas de traitement, donc ils ne présentent pas de symptômes liés au traitement.
Groupes témoinsSymptômes
#2
Comment les symptômes sont-ils évalués ?
Les symptômes sont évalués par des questionnaires ou des examens cliniques dans les deux groupes.
Évaluation des symptômesGroupes témoins
Prévention
2
#1
Les groupes témoins aident-ils à la prévention ?
Oui, ils permettent d'évaluer l'efficacité des interventions préventives par comparaison.
PréventionGroupes témoins
#2
Comment les groupes témoins influencent-ils la prévention ?
Ils fournissent des données sur l'impact des mesures préventives en comparaison avec l'absence d'intervention.
Mesures préventivesGroupes témoins
Traitements
2
#1
Quel type de traitement est comparé ?
Le traitement expérimental est comparé à un placebo ou à un traitement standard dans le groupe témoin.
Traitements expérimentauxGroupes témoins
#2
Comment les résultats sont-ils mesurés ?
Les résultats sont mesurés par des critères prédéfinis, comme l'amélioration des symptômes.
Mesure des résultatsGroupes témoins
Complications
2
#1
Les complications sont-elles observées dans les groupes témoins ?
Les complications peuvent être observées, mais elles ne sont pas dues au traitement expérimental.
ComplicationsGroupes témoins
#2
Comment les complications sont-elles analysées ?
Elles sont analysées en comparant leur fréquence entre le groupe témoin et le groupe traité.
Analyse des complicationsGroupes témoins
Facteurs de risque
2
#1
Les groupes témoins aident-ils à identifier des facteurs de risque ?
Oui, ils permettent de comparer les facteurs de risque entre les groupes traité et témoin.
Facteurs de risqueGroupes témoins
#2
Comment les facteurs de risque sont-ils évalués ?
Ils sont évalués par des questionnaires et des analyses statistiques dans les deux groupes.
Évaluation des facteurs de risqueGroupes témoins
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Groupes témoins : Questions médicales les plus fréquentes",
"headline": "Groupes témoins : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Groupes témoins : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-25",
"dateModified": "2025-04-21",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Groupes témoins"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Méthodes",
"url": "https://questionsmedicales.fr/mesh/D008722",
"about": {
"@type": "MedicalCondition",
"name": "Méthodes",
"code": {
"@type": "MedicalCode",
"code": "D008722",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E05.581"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Groupes témoins",
"alternateName": "Control Groups",
"code": {
"@type": "MedicalCode",
"code": "D035061",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Thomas Steger-Hartmann",
"url": "https://questionsmedicales.fr/author/Thomas%20Steger-Hartmann",
"affiliation": {
"@type": "Organization",
"name": "Bayer Research & Development, Pharmaceuticals, Investigative Toxicology, Berlin, Germany."
}
},
{
"@type": "Person",
"name": "Tania Rivera-Hernandez",
"url": "https://questionsmedicales.fr/author/Tania%20Rivera-Hernandez",
"affiliation": {
"@type": "Organization",
"name": "School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St. Lucia, Queensland, Australia."
}
},
{
"@type": "Person",
"name": "Mark J Walker",
"url": "https://questionsmedicales.fr/author/Mark%20J%20Walker",
"affiliation": {
"@type": "Organization",
"name": "School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St. Lucia, Queensland, Australia."
}
},
{
"@type": "Person",
"name": "Mark R Davies",
"url": "https://questionsmedicales.fr/author/Mark%20R%20Davies",
"affiliation": {
"@type": "Organization",
"name": "Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia."
}
},
{
"@type": "Person",
"name": "Alexander Gurjanov",
"url": "https://questionsmedicales.fr/author/Alexander%20Gurjanov",
"affiliation": {
"@type": "Organization",
"name": "Bayer Research & Development, Pharmaceuticals, Investigative Toxicology, Berlin, Germany. Electronic address: alexander.gurjanov@bayer.com."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Language disorders in patients with striatal lesions: Deciphering the role of the striatum in language performance.",
"datePublished": "2023-06-01",
"url": "https://questionsmedicales.fr/article/37354871",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cortex.2023.04.016"
}
},
{
"@type": "ScholarlyArticle",
"name": "Access to Speech and Language Services and Service Providers for Children With Speech and Language Disorders.",
"datePublished": "2022-05-25",
"url": "https://questionsmedicales.fr/article/35613324",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1044/2022_AJSLP-21-00287"
}
},
{
"@type": "ScholarlyArticle",
"name": "Therapeutic hypnosis in a child with a written language disorder.",
"datePublished": "2022-10-05",
"url": "https://questionsmedicales.fr/article/36197740",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/00029157.2022.2108746"
}
},
{
"@type": "ScholarlyArticle",
"name": "Telepractice in the diagnosis and treatment of pediatric speech-language disorders: The opinions and experiences of speech-language pathologists.",
"datePublished": "2023-04-19",
"url": "https://questionsmedicales.fr/article/37116275",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ijporl.2023.111560"
}
},
{
"@type": "ScholarlyArticle",
"name": "Activities and participation of children with language disorders in outpatient care according to the ICF.",
"datePublished": "2023-08-04",
"url": "https://questionsmedicales.fr/article/37556703",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1590/2317-1782/20232022007pt"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Techniques d'investigation",
"item": "https://questionsmedicales.fr/mesh/D008919"
},
{
"@type": "ListItem",
"position": 3,
"name": "Méthodes",
"item": "https://questionsmedicales.fr/mesh/D008722"
},
{
"@type": "ListItem",
"position": 4,
"name": "Groupes témoins",
"item": "https://questionsmedicales.fr/mesh/D035061"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Groupes témoins - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Groupes témoins",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Groupes témoins",
"description": "Comment identifier un groupe témoin ?\nQuel est le rôle d'un groupe témoin ?\nComment choisir un groupe témoin ?\nLes groupes témoins sont-ils toujours nécessaires ?",
"url": "https://questionsmedicales.fr/mesh/D035061?mesh_terms=Language+Disorders#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Groupes témoins",
"description": "Les groupes témoins montrent-ils des symptômes ?\nComment les symptômes sont-ils évalués ?",
"url": "https://questionsmedicales.fr/mesh/D035061?mesh_terms=Language+Disorders#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Groupes témoins",
"description": "Les groupes témoins aident-ils à la prévention ?\nComment les groupes témoins influencent-ils la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D035061?mesh_terms=Language+Disorders#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Groupes témoins",
"description": "Quel type de traitement est comparé ?\nComment les résultats sont-ils mesurés ?",
"url": "https://questionsmedicales.fr/mesh/D035061?mesh_terms=Language+Disorders#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Groupes témoins",
"description": "Les complications sont-elles observées dans les groupes témoins ?\nComment les complications sont-elles analysées ?",
"url": "https://questionsmedicales.fr/mesh/D035061?mesh_terms=Language+Disorders#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Groupes témoins",
"description": "Les groupes témoins aident-ils à identifier des facteurs de risque ?\nComment les facteurs de risque sont-ils évalués ?",
"url": "https://questionsmedicales.fr/mesh/D035061?mesh_terms=Language+Disorders#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un groupe témoin ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un groupe témoin est constitué de participants similaires au groupe traité, mais sans intervention."
}
},
{
"@type": "Question",
"name": "Quel est le rôle d'un groupe témoin ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il permet d'évaluer l'effet d'un traitement en comparant les résultats avec ceux du groupe traité."
}
},
{
"@type": "Question",
"name": "Comment choisir un groupe témoin ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le choix doit se baser sur des critères d'inclusion similaires à ceux du groupe traité."
}
},
{
"@type": "Question",
"name": "Les groupes témoins sont-ils toujours nécessaires ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont essentiels pour établir des comparaisons valides dans les études cliniques."
}
},
{
"@type": "Question",
"name": "Les groupes témoins montrent-ils des symptômes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ils ne reçoivent pas de traitement, donc ils ne présentent pas de symptômes liés au traitement."
}
},
{
"@type": "Question",
"name": "Comment les symptômes sont-ils évalués ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes sont évalués par des questionnaires ou des examens cliniques dans les deux groupes."
}
},
{
"@type": "Question",
"name": "Les groupes témoins aident-ils à la prévention ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils permettent d'évaluer l'efficacité des interventions préventives par comparaison."
}
},
{
"@type": "Question",
"name": "Comment les groupes témoins influencent-ils la prévention ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils fournissent des données sur l'impact des mesures préventives en comparaison avec l'absence d'intervention."
}
},
{
"@type": "Question",
"name": "Quel type de traitement est comparé ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement expérimental est comparé à un placebo ou à un traitement standard dans le groupe témoin."
}
},
{
"@type": "Question",
"name": "Comment les résultats sont-ils mesurés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les résultats sont mesurés par des critères prédéfinis, comme l'amélioration des symptômes."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles observées dans les groupes témoins ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent être observées, mais elles ne sont pas dues au traitement expérimental."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles analysées ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont analysées en comparant leur fréquence entre le groupe témoin et le groupe traité."
}
},
{
"@type": "Question",
"name": "Les groupes témoins aident-ils à identifier des facteurs de risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils permettent de comparer les facteurs de risque entre les groupes traité et témoin."
}
},
{
"@type": "Question",
"name": "Comment les facteurs de risque sont-ils évalués ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont évalués par des questionnaires et des analyses statistiques dans les deux groupes."
}
}
]
}
]
}
School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St. Lucia, Queensland, Australia.
School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St. Lucia, Queensland, Australia.
Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
The classical neural model of language refers to a cortical network involving frontal, parietal and temporal regions. However, patients with subcortical lesions of the striatum have language difficult...
The purposes of this study were to (a) examine children's access to services for their speech and language disorders during their lifetimes; (b) identify any child, disorder, and family characteristic...
Data from the 2012 National Health Interview Survey were used for this retrospective cohort study. Our sample included 491 children (ages 3;0-17;11 [years;months]) with speech disorders and 333 childr...
Approximately 75% of children with speech and language disorders had ever received services for their difficulties. Privately insured children and children with co-occurring conditions were more likel...
Most children with speech and language disorders received services. However, disparities existed by race/ethnicity, health insurance type, co-occurring diagnoses, and disorder duration (speech only). ...
https://doi.org/10.23641/asha.19799389....
Children with Attentional Deficit Hyperactivity Disorder (ADHD) frequently have low self-awareness and attentional deficits on which therapeutic hypnosis can have a positive impact. Here we investigat...
This prospective cross-sectional study aimed to investigate the opinions and experiences with telepractice (TP) of Dutch-speaking speech-language pathologists (SLPs) living in the Dutch-speaking part ...
Twenty-nine Dutch-speaking speech-language pathologists living in Flanders (age category 20-30 years: n = 16/29, 55.2%, 31-40 years: n = 10/29, 34.2%, 41-50 years: n = 2/29, 6.9%, 51-60 years: n = 1/2...
The study showed a statistically significant association between years of clinical experience of SLPs and their opinion that TP does not provide more options in a clinical setting compared to face-to-...
Expertise in multiple domains of pediatric speech-language therapy resulted in experiencing more added value of TP during the corona pandemic, possibly because of the experience of multiple different ...
To identify the main categories of the Activities and Participation component of the International Classification of Functioning, Disability, and Health and to verify the association with age, gender,...
This is an analytical and cross-sectional observational study, carried out with secondary data from 32 medical records of children with the majority male, mean age of 41.03 months, in early childhood ...
The descriptive analysis of the pre-selected categories allowed us to verify a high number of "Not informed" answers, with a higher percentage in vocal expression without speech (d331) performance (93...
Difficulties were identified in several categories of the Activities and Participation component and statistically significant associations between them and sociodemographic data and speech therapy di...
To examine the speech, language, and communication skills of school-age children with attention deficit and hyperactive disorder....
The sample of the study consists of attention deficit and hyperactivity disorder (...
SPSS program was used in the analysis of the data. Mann Whitney...
It has been concluded that language, speech, and working memory skills of children with attention deficit and hyperactivity disorder are lower than their peers with typical development. Speech and lan...
Theoretical models posit abnormalities in cortico-striatal pathways in two of the most common neurodevelopmental disorders (Developmental dyslexia, DD, and Attention deficit hyperactive disorder, ADHD...
Our results show that, relative to neurotypicals, DD individuals showed an impairment in model-free but not in model-based learning, whereas in ADHD the ability to use both model-free and model-based ...
Thus, learning impairments in DD may be linked to a selective deficit in the ability to form action-outcome associations based on previous history, whereas in ADHD some learning deficits may be relate...
The prevalence of language disorder in youth offenders far exceeds rates reported in community samples. Youth involved in the justice system are also at increased risk of a range of psychiatric disord...
To explore the co-occurrence of language disorder and anxiety and depression in youth offenders....
A systematic literature search of six databases (CINAHL, ERIC, Medline, PyscINFO, PubMED, Scopus) was conducted (September 2021) using key search terms relevant to the systematic review question. Stud...
Eight studies met the eligibility criteria. A range of measures was used to assess language abilities across samples. Only two studies directly addressed the relationship between language disorder and...
Although the results did not support a significant relationship between language disorder and internalizing mental health problems in youth offenders, the two appear to occur comorbidly as evidenced b...
What is already known on this subject The markedly high rates of language disorder in youth involved in the justice system have been widely reported. It is also known that externalizing mental health ...
To characterize changes in the functioning aspects, in the perception of children and adolescents with speech and language disorders under speech-language follow-up, using the ICF....
Descriptive, analytical and longitudinal research, with a qualitative and quantitative approach, whose sample consisted of 60 children and adolescents: 30 with speech and language disorders and 30 wit...
The use of ICF allowed characterizing changes resulting from speech-language follow-up. Participants with speech and language disorders presented a decrease in the magnitude of the qualifiers in the c...
The findings show changes in components of Body Functions, Activities and Participation, and the influence of Environmental Factors after speech-language follow-up, in the perception of the studied gr...
To evaluate the association between antibiotic use during pregnancy or early infancy and the risk of neurodevelopmental disorders in children....
Nationwide population based cohort study and sibling analysis....
Korea's National Health Insurance Service mother-child linked database, 2008-21....
All children live born between 2009 and 2020, followed up until 2021 to compare those with and without antibiotic exposure during pregnancy or early infancy (first six months of life)....
Autism spectrum disorder, intellectual disorder, language disorder, and epilepsy in children. After 1:1 propensity score matching based on many potential confounders, hazard ratios with 95% confidence...
After propensity score matching, 1 961 744 children were identified for the pregnancy analysis and 1 609 774 children were identified for the early infancy analysis. Although antibiotic exposure durin...
In this large cohort study, antibiotic exposure during pregnancy or early infancy was not associated with an increased risk of autism spectrum disorder, intellectual disorder, or language disorder in ...
